{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:15:32Z","timestamp":1788394532072,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Fufang Yinhua Jiedu (FFYH) granules are recommended for treating coronavirus pneumonia (COVID-19) in China. However, its anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity and clinical efficacy against COVID-19 remain to be confirmed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>Our study aimed to investigate the anti-SARS-CoV-2 effect and potential mechanism of FFYH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>The activity of FFYH against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was evaluated via cell pathogenic effects, immunoblotting, immunofluorescence staining, and qRT-PCR. The potential mechanism of FFYH against SARS-CoV-2 was investigated by immunoblotting. One head-to-head randomized controlled trial was designed to evaluate the clinical efficacy of FFYH in mild COVID-19. Two hundred patients were randomly recruited to receive either FFYH or LHQW (Lianhua Qingwen) granules.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The <jats:italic>in vitro<\/jats:italic> results indicated that FFYH effectively inhibited SARS-CoV-2 replication by suppressing CPE and decreasing viral RNA and protein expression. A time-of-drug-addition assay confirmed that FFYH mainly targeted the binding and replication stages of the SARS-CoV-2 life cycle. Mechanistic studies revealed that blocking SARS-CoV-2-triggered autophagy may be the primary mechanism by which FFYH protects against SARS-CoV-2 infection by regulating the phosphatidylinositol 3-kinase (PI3K)\/AKT\/mammalian target of rapamycin (mTOR) signaling pathway. Clinical results confirmed that FFYH effectively shortened the recovery time of clinical symptoms and viral nucleic acid negativity, improved abnormal hematology parameters, and controlled excessive cytokine responses in mild COVID-19 patients. Subgroup analysis revealed that FFYH improved the recovery time of clinical symptoms, improved hematological parameters, and controlled excessive cytokine storms to a greater extent in the mild COVID-19 male subgroup, abnormal hematology subgroup, and 32\u201342-year-old subgroup than in the corresponding LHQW subgroup (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). No patients progressed to severe or critical cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results indicate that FFYH not only has good anti-viral activity against SARS-CoV-2 but also has significant efficacy against COVID-19, indicating that FFYH may be a novel complementary option for treating COVID-19.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1431617","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T04:43:19Z","timestamp":1726461799000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical efficacy of Fufang Yinhua Jiedu (FFYH) granules in mild COVID-19 and its anti-SARS-CoV-2 mechanism by blocking autophagy through inhibiting the AKT\/mTOR signaling pathway"],"prefix":"10.3389","volume":"15","author":[{"given":"Wenlei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tieliang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiang","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2021.09.005","article-title":"Targeting the PI3K\/Akt\/mTOR pathway: a therapeutic strategy in COVID-19 patients","volume":"240","author":"Abu-Eid","year":"2021","journal-title":"Immunol. Lett."},{"key":"B2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00277-020-04256-3","article-title":"Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection","volume":"100","author":"Algassim","year":"2021","journal-title":"Ann. Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.apsb.2022.02.019","article-title":"Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2","volume":"12","author":"Aliyari","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"B4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"156287","DOI":"10.1016\/j.cyto.2023.156287","article-title":"Emerging aspects of cytokine storm in COVID-19: the role of proinflammatory cytokines and therapeutic prospects","volume":"169","author":"Dharra","year":"2023","journal-title":"Cytokine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20200817","article-title":"Blood routine test in mild and common 2019 coronavirus (COVID-19) patients","volume":"40","author":"Djakpo","year":"2020","journal-title":"Biosci. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"100940","DOI":"10.1016\/j.jbior.2022.100940","article-title":"IL-7 and IL-7R in health and disease: an update through COVID times","volume":"87","author":"Fernandes","year":"2023","journal-title":"Adv. Biol. Regul."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1038\/s41467-021-24007-w","article-title":"SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals","volume":"12","author":"Gassen","year":"2021","journal-title":"Nat. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.7150\/ijbs.59272","article-title":"Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy","volume":"18","author":"Jiang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.7150\/thno.49713","article-title":"Immunopathogenesis and treatment of cytokine storm in COVID-19","volume":"11","author":"Kim","year":"2021","journal-title":"Theranostics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.immuni.2021.09.002","article-title":"Early IFN-\u03b1 signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19","volume":"54","author":"Kr\u00e4MER","year":"2021","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jcma.2015.10.009","article-title":"Efficacy and safety of traditional Chinese medicine for the treatment of influenza A (H1N1): a meta-analysis","volume":"79","author":"Li","year":"2016","journal-title":"J. Chin. Med. Assoc."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6082729","DOI":"10.1155\/2016\/6082729","article-title":"Application of traditional Chinese medical herbs in prevention and treatment of respiratory syncytial virus","volume":"2016","author":"Lin","year":"2016","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1016\/j.apsb.2021.09.008","article-title":"Traditional Chinese medicine in COVID-19","volume":"11","author":"Lyu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"B17","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report","volume":"31","author":"Michot","year":"2020","journal-title":"Ann. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"114220","DOI":"10.1016\/j.jep.2021.114220","article-title":"Positive effects of Lianhuaqingwen granules in COVID-19 patients: a retrospective study of 248 cases","volume":"278","author":"Shen","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/s0254-6272(15)30057-1","article-title":"Traditional Chinese medicine for the treatment of influenza: a systematic review and meta-analysis of randomized controlled trials","volume":"34","author":"Wang","year":"2014","journal-title":"J. Tradit. Chin. Med."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcme.2024.03.008","article-title":"Network pharmacology-based study to investigate the mechanism of compound houttuynia mixture against influenza virus infection by suppressing TLR7\/MyD88 signaling pathway","author":"Wei","year":"2024","journal-title":"J. Traditional Complementary Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.14336\/AD.2021.0906","article-title":"Effectiveness and safety of traditional Chinese medicine in treating COVID-19: clinical evidence from China","volume":"12","author":"Xing","year":"2021","journal-title":"Aging Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","article-title":"The signal pathways and treatment of cytokine storm in COVID-19","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jaci.2020.04.027","article-title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","volume":"146","author":"Yang","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.eujim.2014.06.003","article-title":"Traditional Chinese medicine treatments for upper respiratory tract infections\/common colds in Taiwan","volume":"6","author":"Yu","year":"2014","journal-title":"Eur. J. Integr. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.3748\/wjg.v10.i23.3500","article-title":"Effect of integrated traditional Chinese and Western medicine on SARS: a review of clinical evidence","volume":"10","author":"Zhang","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"104882","DOI":"10.1016\/j.phrs.2020.104882","article-title":"The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence","volume":"157","author":"Zhang","year":"","journal-title":"Pharmacol. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1089\/jicm.2021.0352","article-title":"Effectiveness of lianhua qingwen capsule in treatment of asymptomatic COVID-19 patients: a randomized, controlled multicenter trial","volume":"28","author":"Zhang","year":"","journal-title":"J. Integr. Complement. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.21037\/atm-20-6001","article-title":"Lymphocyte percentage and hemoglobin as a joint parameter for the prediction of severe and nonsevere COVID-19: a preliminary study","volume":"8","author":"Zhang","year":"","journal-title":"Ann. Transl. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.3390\/vaccines10122145","article-title":"SARS-CoV-2: an updated review highlighting its evolution and treatments","volume":"10","author":"Zhang","year":"","journal-title":"Vaccines (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"114063","DOI":"10.1016\/j.jep.2021.114063","article-title":"Antiviral effect of fufang yinhua jiedu (FFYH) granules against influenza A virus through regulating the inflammatory responses by TLR7\/MyD88 signaling pathway","volume":"275","author":"Zhang","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.16438\/j.0513-4870.2021-1815","article-title":"Antiviral effect of fufang yinhua jiedu (FFYH) granules against coronavirus and its potential mechanism","volume":"57","author":"Zheng","year":"2022","journal-title":"Acta Pharmaceutica Sinica."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3000605221149292","DOI":"10.1177\/03000605221149292","article-title":"Clinical observation of glucocorticoid therapy for critically ill patients with COVID-19 pneumonia","volume":"51","author":"Zhu","year":"2023","journal-title":"J. Int. Med. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"795315","DOI":"10.3389\/fimmu.2022.795315","article-title":"Immunotherapy of COVID-19: inside and beyond IL-6 signalling","volume":"13","author":"Zizzo","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1431617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T04:43:25Z","timestamp":1726461805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1431617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":33,"alternative-id":["10.3389\/fphar.2024.1431617"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1431617","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"article-number":"1431617"}}